<DOC>
	<DOCNO>NCT01219257</DOCNO>
	<brief_summary>Patients spondylarthritis ( SpA ) ( include ankylose spondylitis , psoriatic arthritis , arthritis part inflammatory bowel disease reactive arthritis ) axial involvement ( spine ) well peripheral inflammation joint entheses ( tendon ligament anchor bone ) . Patients high disease activity SpA may need biological treatment ( anti-TNF alpha ) , expensive medication . Thus necessary sensitive method assess response treatment . Ultrasonography ( US ) validate reliable method assess disease activity joint tendon , may use follow treatment response . The present study include patient SpA start anti-TNF alpha treatment ( first biologic medication switch new biologic treatment ) . The study extension ongoing NORDMARD study ( Norwegian longitudinal observational study arthritic patient start disease-modifying treatment ) . The patient examine use US 38 joint 14 entheses baseline 3 , 6 12 month . The objective explore US method ass peripheral inflammatory activity evaluation response medication well compare US pathology clinical laboratory finding .</brief_summary>
	<brief_title>Longitudinal ULtrasonographic Study Patients With Spondylarthritis Starting Biological Therapy</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<criteria>SpA Planning start antiTNF alpha treatment Patients able communicate Norwegian able fill questionnaires Surgery 5 joints/entheses examine US</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>SpA</keyword>
	<keyword>Anti-TNF alpha treatment</keyword>
	<keyword>Ultrasonography</keyword>
	<keyword>Synovitis</keyword>
	<keyword>Enthesitis</keyword>
</DOC>